Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 117
- Registration Number
- NCT06413992
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT06376721
- Locations
- 🇨🇳
Liang Wang, Beijing, Beijing, China
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 57
- Registration Number
- NCT06363825
- Locations
- 🇨🇳
Xinhua Chen, Fuzhou, China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 300
- Registration Number
- NCT06333561
- Locations
- 🇨🇳
Chinese PLA General hospital, Beijing, Beijing, China
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 12
- Registration Number
- NCT06326736
- Locations
- 🇨🇳
Wang Sizhen, Nanjing, Jiangsu, China
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 240
- Registration Number
- NCT06323382
- Locations
- 🇨🇳
Chinese PLA hospital, Beijing, Beijing, China
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Harbin Medical University
- Target Recruit Count
- 48
- Registration Number
- NCT06304545
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06289062
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06288360
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Beiing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, Chongqing, China
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT06288373
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Beiing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University), Chongqing, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.